Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 6Gastrointestinal 3Other solid neoplasm 2Other 2Other neoplasm 1Gynecologic 1Genitourinary 1Classical hematology 1

Conditions

Ovarian Neoplasms 1Fanconi Anemia, Complementation Group D1 1Breast Neoplasms 1

Interventions

Cytarabine 13fludarabine phosphate 10Etoposide 8Methotrexate 7Cyclophosphamide 7Busulfan 7Idarubicin 6Daunorubicin 6tipifarnib 5Peripheral Blood Stem Cell Transplantation 5Filgrastim 5Cyclosporine 5Antilymphocyte Serum 5Vorinostat 4Tacrolimus 4Radiotherapy 4Mitoxantrone 4Lenalidomide 4Epoetin Alfa 4Azacitidine 4sargramostim 3merphos 3epoetin beta 3Topotecan 3Thioguanine 3Methylprednisolone 3Granulocyte-Macrophage Colony-Stimulating Factor 3Dexamethasone 3Decitabine 3Biopsy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Counseling × Classical hematology × Clear all
NCT00001806 2019-12-12

Methods in Education for Breast Cancer Genetics

National Institutes of Health Clinical Center (CC)

Phase 3 Completed
170 enrolled
BreastClassical hematologyGynecologic

Fanconi Anemia, Complementation Group D1, Breast Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡